Literature DB >> 11791119

E1A: tumor suppressor or oncogene? Preclinical and clinical investigations of E1A gene therapy.

N T Ueno1, D Yu, M C Hung.   

Abstract

In the late 1980s, we have shown that the E1A gene can downregulate HER-2/neu overexpression, thus reversing the tumorigenic and metastatic phenotype. Further, E1A can function as a tumor suppressor gene by inducing apoptosis and inhibiting metastasis. At The University of Texas M. D. Anderson Cancer Center, we have been investigating the adenovirus type 5 E1A gene as a potential therapeutic gene in breast and ovarian cancer since 1995 by using cationic liposome as gene delivery system. In this chapter, we recount our development of E1A as a therapeutic gene.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11791119     DOI: 10.1007/bf02967526

Source DB:  PubMed          Journal:  Breast Cancer        ISSN: 1340-6868            Impact factor:   4.239


  8 in total

1.  Comparative sequence analysis of the largest E1A proteins of human and simian adenoviruses.

Authors:  Nikita Avvakumov; Russ Wheeler; Jean Claude D'Halluin; Joe S Mymryk
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

2.  Downregulation of microRNA miR-520h by E1A contributes to anticancer activity.

Authors:  Jen-Liang Su; Poshen B Chen; Ya-Huey Chen; Shang-Chih Chen; Yi-Wen Chang; Yi-Hua Jan; Xiaoyun Cheng; Michael Hsiao; Mien-Chie Hung
Journal:  Cancer Res       Date:  2010-05-25       Impact factor: 12.701

3.  Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer.

Authors:  Qingqing Ding; Longfei Huo; Jer-Yen Yang; Weiya Xia; Yongkun Wei; Yong Liao; Chun-Ju Chang; Yan Yang; Chien-Chen Lai; Dung-Fang Lee; Chia-Jui Yen; Yun-Ju Rita Chen; Jung-Mao Hsu; Hsu-Ping Kuo; Chun-Yi Lin; Fuu-Jen Tsai; Long-Yuan Li; Chang-Hai Tsai; Mien-Chie Hung
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

Review 4.  Gene therapy for carcinoma of the breast.

Authors:  M A Stoff-Khalili; P Dall; D T Curiel
Journal:  Cancer Gene Ther       Date:  2006-01-06       Impact factor: 5.987

5.  FOXO3a-Dependent Mechanism of E1A-Induced Chemosensitization.

Authors:  Jen-Liang Su; Xiaoyun Cheng; Hirohito Yamaguchi; Yi-Wen Chang; Chao-Feng Hou; Dung-Fang Lee; How-Wen Ko; Kuo-Tai Hua; Ying-Nai Wang; Michael Hsiao; Poshen B Chen; Jung-Mao Hsu; Robert C Bast; Gabriel N Hortobagyi; Mien-Chie Hung
Journal:  Cancer Res       Date:  2011-09-12       Impact factor: 12.701

6.  A novel hTERT promoter-driven E1A therapeutic for ovarian cancer.

Authors:  Xiaoming Xie; Jennifer L Hsu; Min-Gew Choi; Weiya Xia; Hirohito Yamaguchi; Chun-Te Chen; Bon Q Trinh; Zhen Lu; Naoto T Ueno; Judith K Wolf; Robert C Bast; Mien-Chie Hung
Journal:  Mol Cancer Ther       Date:  2009-08-11       Impact factor: 6.261

Review 7.  Objective assessment of cancer genes for drug discovery.

Authors:  Mishal N Patel; Mark D Halling-Brown; Joseph E Tym; Paul Workman; Bissan Al-Lazikani
Journal:  Nat Rev Drug Discov       Date:  2013-01       Impact factor: 84.694

8.  Gene therapy for colorectal cancer by an oncolytic adenovirus that targets loss of the insulin-like growth factor 2 imprinting system.

Authors:  Zhen-Lin Nie; Yu-Qin Pan; Bang-Shun He; Ling Gu; Li-Ping Chen; Rui Li; Ye-Qiong Xu; Tian-Yi Gao; Guo-Qi Song; Andrew R Hoffman; Shu-Kui Wang; Ji-Fan Hu
Journal:  Mol Cancer       Date:  2012-11-21       Impact factor: 27.401

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.